Graviton Bioscience, founded in 2018 and based in New York, is a private, clinical-stage biotech developing a portfolio of selective ROCK2 inhibitors. The company's platform targets the restoration of biological equilibrium to treat a range of fibrotic, autoimmune, and CNS disorders. It has advanced its lead programs into clinical development, supported by strategic partnerships with Ovid Therapeutics, Sino Biopharmaceutical, and an equity investment from Sanofi.
Fibrotic DiseasesAutoimmune DiseasesCentral Nervous System (CNS) DiseasesMetabolic Syndromes
Technology Platform
Platform for developing selective small molecule inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2), aimed at restoring biological homeostasis to treat disease.
Funding History
2
Total raised:$140M
Series B$87MCormorant Asset Management
Series A$53MCormorant Asset Management
Opportunities
The selective ROCK2 platform addresses massive markets with high unmet need, including obesity and fibrotic diseases.
Strategic partnerships with Sanofi and Ovid provide funding, validation, and a path to commercialization.
Positive clinical data in the coming 12-24 months could significantly increase company valuation and attract further investment or acquisition interest.
Risk Factors
High clinical risk inherent in a novel, single-mechanism platform; efficacy or safety failures would impact the entire portfolio.
Intense competition in target indications (e.g., obesity) from established and novel therapies.
Dependency on partnership milestones and funding for operational runway.
Competitive Landscape
ROCK2 is a validated but competitive target, with other companies having advanced inhibitors (e.g., belumosudil for graft-versus-host disease). Graviton's focus on selectivity and homeostasis differentiates its approach. It competes in large markets like obesity against GLP-1 agonists and in fibrosis against a growing number of anti-fibrotic agents, requiring superior clinical profiles to succeed.
